Current Legislation
STOP THE BIG PHARMA MONEY GRAB:
REJECT ASSEMBLY BILL 910 AND SENATE BILL 41
Assembly Bill 910 and Senate Bill 41 are Big Pharma-backed proposals that would ban pay-for-performance incentives in the private health care marketplace—eliminating a key tool that employers and unions use to lower prescription drug costs for hardworking Californians and their families.
Instead of lowering the cost of prescription drugs, these bills would undermine market-based savings, drive up insurance premiums and increase out-of-pocket costs for millions of California residents who rely on their employer or union for their health coverage.
What AB 910 and SB 41 Would Do:
-
Increase Health Care Costs for Millions of Californians
-
Reward Big Pharma at the Expense of California Patients, Businesses, and Union Members
-
Do Nothing to Lower Prescription Drug Prices
Why CAPA Opposes AB 910 and SB 41
Employers and unions negotiate better deals on prescription drugs by choosing to hire pharmacy benefit managers (PBMs), which pool their negotiating power to unlock savings for health plan sponsors, and the patients and families on these plans.
Assembly Bill 910 and Senate Bill 41 would ban pay-for-performance incentives in the private health care marketplace that are essential for helping California employers and unions secure significant savings on prescription drugs. Make no mistake: these bills will directly lead to higher premium costs for patients.
These bills are not about protecting patients—they’re about protecting Big Pharma’s profits.
Californians can’t afford legislation that increases health care costs while doing nothing to lower prescription drug prices.